Опыт применения эмицизумаба у ребенка с тяжелой формой ингибиторной гемофилии А и затрудненным венозным доступом

1. Report on research work “Determination of the number of patients with a diagnosis of Hemophilia A with and without an inhibitor in the Russian Federation”. M., 2019. P. 2. (In Russ.).

2. Geraghty S., Dunkley T., Harrington C., Lindvall K., Maahs J., Sek J. Practice patterns in haemophilia A therapy: global progress towards optimal care. Haemophilia 2006;12(1):75–81. doi: 10.1111/j.1365-2516.2006.01189.x.

3. Buckley B., Dreyfus J., Prasad M., Gayle J., Kendter J., Hall E. Burden of Illness Among Pediatric Hemophilia Patients with and without Central Venous Access Devices Treated in U.S. Hospitals. Blood 2015;126(23):4447. doi:10.1182/blood.V126.23.4447.4447.

4. Van Dijk K., Van Der Bom J.G., Bax K.M.A., Van Der Zee D.C., Van Den Berg M.H. Use of implantable venous access devices in children with severe hemophilia: benefi ts and burden. Haematologica 2004;89(2):189–94. PMID: 15003894.

5. Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004;18(2):93–100. doi: 10.1016/S0268-960X(03)00043-2.